(Q36648116)

15 August 2017

Bone resorption predicts for skeletal complications in metastatic bone disease (English)

1 reference

15 August 2017

1 reference

J E Brown

1

1 reference

15 August 2017

C S Thomson

2

1 reference

15 August 2017

S P Ellis

3

1 reference

15 August 2017

S A Gutcher

4

1 reference

15 August 2017

O P Purohit

5

1 reference

15 August 2017

R E Coleman

6

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 2003

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

89

1 reference

15 August 2017

11

1 reference

15 August 2017

2031-2037

1 reference

Efficacy and safety of zoledronic acid in the treatment of bone metastases associated with lung cancer and other solid tumors

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376859

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376859

Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376859

Analysis of skeletal-related events in breast cancer and response to therapy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376859

Bone markers in the management of metastatic bone disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376859

Metabolic effects of pamidronate in patients with metastatic bone disease

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376859

Advanced breast cancer: use of resources and cost implications

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376859

The clinical course of bone metastases from breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376859

Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376859

Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376859

Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2376859

A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine

20 September 2018

1 reference

12 December 2020

Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group

1 reference

12 December 2020

The usefulness of bone turnover in predicting the response to transdermal estrogen therapy in postmenopausal osteoporosis

1 reference

12 December 2020

Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease

1 reference

12 December 2020

Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group

1 reference

12 December 2020

Markers of bone resorption in patients treated with pamidronate

1 reference

12 December 2020

Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6601437

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

14647134

1 reference